Laura Huppert, MD

Articles

Novel and Emerging Strategies for HER2+ Breast Cancer With Brain Metastases

February 19th 2025

Panelists discuss how sequential therapy selection for patients with HER2+ breast cancer with progressive brain metastases requires careful consideration of prior treatments, patterns of progression, symptom burden, and available clinical trials, while balancing the need for both systemic disease control and CNS -specific approaches.

Insights From DESTINY-Breast12 Evaluating T-DXd in HER2+ Breast Cancer and Active and Stable Brain Metastases

February 19th 2025

Panelists discuss how the DESTINY-Breast12 trial evaluated trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer (mBC) with brain metastases, demonstrating encouraging intracranial responses and overall survival outcomes while maintaining a manageable safety profile consistent with previous T-DXd studies.

Precision in CNS Targeting: Optimizing Management of Brain Metastases in HER2+ Breast Cancer

February 12th 2025

Panelists discuss how treatment selection for patients with HER2+ breast cancer with brain metastases requires careful consideration of factors such as metastatic burden, symptomatology, and prior therapies, typically incorporating both local approaches and systemic agents with CNS activity while accounting for individual patient characteristics such as performance status, comorbidities, and preferences in developing personalized treatment plans.

Evolving Paradigms in HER2+ Advanced Breast Cancer With Brain Metastases

February 12th 2025

Panelists discuss how patients with HER2+ breast cancer frequently develop brain metastases, with recent pivotal trials such as HER2CLIMB and DESTINY-Breast03 demonstrating improved intracranial responses with newer agents such as tucatinib, and how trastuzumab deruxtecan leads to evolving standards of care (SOC) that now incorporate these targeted therapies alongside traditional local therapies.

Proactive AE Management and Prophylactic Strategies With TADCs in Breast Cancer

February 5th 2025

Panelists discuss how trastuzumab deruxtecan’s (T-DXd's) key adverse events (AEs) include interstitial lung disease, neutropenia, and nausea/fatigue, emphasizing the importance of proactive monitoring, early intervention through coordinated multidisciplinary care, and comprehensive patient education with clear communication channels for reporting symptoms.

Patient-Reported Outcomes and Quality of Life Data With T-DXd in HER2-(Ultra) Low mBC

February 5th 2025

Panelists discuss how trastuzumab deruxtecan (T-DXd) demonstrated favorable patient-reported outcomes and quality of life measures in HER2-low hormone receptor-positive metastatic breast cancer patients in DESTINY-Breast06, suggesting it could be a well-tolerated therapeutic option that maintains patients' daily functioning while providing clinical benefit.

Emerging Data and Treatment Considerations in HER2 Ultralow Breast Cancer

January 29th 2025

Panelists discuss how emerging data on HER2-ultralow breast cancer is informing treatment decisions, particularly regarding the potential role of trastuzumab deruxtecan, while acknowledging the need for careful patient selection and consideration of traditional treatment sequences.

T-DXd in HER2-Low Disease: DESTINY-Breast06 Data and Patient Selection Insights

January 29th 2025

Panelists discuss how DESTINY-Breast06 demonstrated meaningful clinical activity of trastuzumab deruxtecan in both HER2-low and ultralow metastatic breast cancer populations.

ADCs in HER2-Low Breast Cancer: Insights From DESTINY-Breast04, TROPiCS-02, and TROPION-Breast02

January 22nd 2025

Panelists discuss how clinical trials like DESTINY-Breast04, TROPiCS-02, and TROPION-Breast01 have revolutionized treatment options for HER2-low advanced breast cancer by validating novel targeted therapies and antibody-drug conjugates.

Precision Medicine in Breast Cancer: Evolving Paradigms in HER2 Testing and Clinical Implications

January 15th 2025

Panelists discuss how evolving HER2 classification methods and recent trial data are reshaping treatment approaches for advanced breast cancer, particularly regarding the clinical significance of HER2-low and ultralow categories.

Dr Huppert on Survival Outcomes of Patients With Metastatic Breast Cancer and Leptomeningeal Disease

January 9th 2025

Laura A. Huppert, MD, discusses survival outcomes of patients with metastatic breast cancer and leptomeningeal disease according to disease subtype.

Effects of trastuzumab deruxtecan (T-DXd) on health-related quality of life (HRQOL): DESTINY-Breast12 (DB-12) results

December 18th 2024

Dr. Laura Huppert presents key data from the DESTINY-Breast12 study, showcasing the effects of trastuzumab deruxtecan on health-related quality of life and neurological function in HER2+ metastatic breast cancer patients, with findings demonstrating preserved quality of life and neurological stability, regardless of brain metastasis status.

Best Practices in Managing Patients on Capivasertib

November 4th 2024

Panelists discuss the key advice they would offer to fellow physicians, nurse practitioners, advanced practice providers, and pharmacists involved in the care of patients on capivasertib, emphasizing best practices for patient management and communication.

Managing Capivasertib Side Effects: Strategies for Educating, Monitoring, and Addressing Rash and Hyperglycemia

November 4th 2024

Panelists discuss their approach to monitoring and managing hyperglycemia in patients receiving capivasertib and providing education about it, including when to involve endocrinology and how management strategies may differ for patients with preexisting diabetes.

Adverse Event Management: Strategies for Reducing Diarrhea Risk in Capivasertib Therapy

October 28th 2024

Panelists discuss the strategies they employ to manage adverse events in patients starting capivasertib, including minimizing the risk of diarrhea through dietary considerations and patient education, as well as approaches for monitoring and managing rash associated with the treatment and providing education about it.

Clinical Experience with Capivasertib

October 28th 2024

Panelists discuss their clinical experiences with capivasertib, focusing on patient tolerability and the management of adverse effects associated with this targeted therapy.

Overview of the CAPItello-291 Trial

October 21st 2024

Panelists discuss the findings of the CAPItello-291 trial, which investigated capivasertib combined with fulvestrant in advanced hormone receptor–positive, HER2-negative breast cancer, leading to its approval in November 2023 and highlighting its potential as a new targeted therapy option in the second-line setting due to the prevalence of PIK3CA, AKT1, and PTEN alterations.

Role of PI3K/AKT/PTEN Pathway in HR+/HER2- Advanced Breast Cancer

October 21st 2024

Panelists discuss how aberrations in the PI3K/AKT/PTEN pathway drive treatment resistance and disease progression following first-line therapy in hormone receptor–positive, HER2-negative advanced breast cancer, emphasizing the critical role of repeat biomarker testing to guide ongoing treatment strategies and enhance patient outcomes.

First-Line Treatment Strategies for HR+/HER2- Advanced Breast Cancer

October 14th 2024

Panelists discuss how to approach selecting first-line treatment options for hormone receptor–positive, HER2-negative advanced breast cancer by providing an overview of standard-of-care options and highlighting the primary considerations that guide treatment selection.

Insights on Biomarker Testing in HR+/HER2- Advanced Breast Cancer

October 14th 2024

Panelists discuss how biomarker testing plays a critical role in hormone receptor–positive, HER2-negative advanced breast cancer, emphasizing the timing of testing, the relevance of specific genomic assays, and the significant impact on prognosis and treatment decisions.